Terminated PHASE2 INTERVENTIONAL 1-arm NCT01510756

Sorafenib for the Treatment of Chronic Lymphocytic Leukemia (CLL)

A Phase II Translational Study of Sorafenib for the Treatment of Chronic Lymphocytic Leukemia Patients

Sponsor: Bayer

Interventions Sorafenib

Updated 6 times since 2017 Last updated: Dec 16, 2015 Started: Dec 31, 2011 Primary completion: May 31, 2014 Completion: Dec 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

slow enrollment

Other terminated trials from Bayer

See all terminations from Bayer

Other Chronic Lymphocytic Leukemia trials with similar outcome

Browse all Chronic Lymphocytic Leukemia trials

A PHASE2 clinical study on Chronic Lymphocytic Leukemia, this trial is terminated or withdrawn. The trial is conducted by Bayer and has accumulated 6 data snapshots since 2011. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2

First recorded

Dec 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bayer
Thomas Kipps

Data source: University of California, San Diego

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• La Jolla, United States